Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab Plus Chemoradiotherapy for Locally Advanced Cervical Squamous Cell Carcinoma
NCT06333821Phase 3Not yet recruiting
- Start
- Apr 2024
- Primary completion
- Apr 2030
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial in cervical squamous cell carcinoma (CSCC) comparing Nimotuzumab+chemoradiotherapy with Placebo+chemoradiotherapy (2 arms). Primary endpoint: Progression-Free Survival at 5 years. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
nimotuzumab
03
Conditions
cervical squamous cell carcinoma (CSCC)
Beyond the preview
Go deeper on NCT06333821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06333821.